Changes in the HIV type 1 envelope gene from non-subtype B HIV type 1-infected children in Kenya

AIDS Research and Human Retroviruses

Volumn 25, Issue 2, 2009, Pages 141-147

  Lwembe, Raphael ^a,b   Lihana, Raphael W ^a,b   Ochieng', Washingtone ^a   Panikulam, Annie ^c   Mongoina, Charles O ^c   Palakudy, Tresa ^c   De Koning, Heleen ^b   Ishizaki, Azumi ^b   Kageyama, Seiji ^b   Musoke, Rachel ^c   Owens, Mary ^c   Songok, Elijah M ^a   Okoth, Frederick A ^a   Ichimura, Hiroshi ^b  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b KANAZAWA UNIVERSITY   (Japan)

^c Nyumbani Children's Home   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AMINO ACID SEQUENCE; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE COURSE; ENVELOPE GENE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KENYA; MAJOR CLINICAL STUDY; PLASMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION;

ADOLESCENT; AMINO ACID SEQUENCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; KENYA; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; RECEPTORS, HIV; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; VIRAL LOAD; VIRUS INTERNALIZATION; YOUNG ADULT;

EID: 60849094093     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0144     Document Type: Article

References (41)

1. Moser B: Chemokines and HIV: A remarkable synergism. Trends Microbiol 1997;5:88-90.
2. Berger E, Doms R, Fenyo E, et al.: A new classification for HIV-1. Nature 1998;391:240.
3. Schuitemaker H, Kootstra N, de Goede R, et al.: Monocytotropic HIV-1 variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J Virol 1991;65:356-363.
4. Shankarappa R, Margolick J, Gange S, et al.: Consistent viral evolutionary changes associated with the progression of HIV type 1 infection. J Virol 1999;73:489-502.
5. Zhu T, Mo H, Wang N, et al.: Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993;261:1179-1181.
6. Scarlatti G, Tresoldi E, Bjorndal A, et al.: In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997;3:1259-1265.
7. Connor RI, Sheridan KE, Ceradini D, et al.: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185:621-628.
8. De Rossi A, Masiero S, Giaquinto C, et al.: Dynamics of viral replication in infants with vertically acquired human immunodeficiency virus type 1 infection. J Clin Invest 1996;97:323-330.
9. Hunt P, Harrigan P, Huang W, et al.: Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 2006;194:926-930.
10. Tersmette M, Gruters R, de Wolf F, et al.: Evidence for a role of virulent HIV variants in the pathogenesis of acquired immunodeficiency syndrome: Studies on sequential HIV isolates. J Virol 1989;63:2118-2125.
11. Tersmette M, de Goede RE, Al BJ, et al.: Differential syncytium-inducing capacity of human immunodeficiency virus isolates: Frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol 1988;62:2026-2032.
12. Schuitemaker H, Koot M, Kootstra NA, et al.: Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of diseases is associated with a shift from monocytotropic to T-cell tropic virus population. J Virol 1992;66:1354-1360.
13. Koot M, Keet IP, Vos AH, et al.: Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993;118:681-688.
14. Richman DD and Bozzette SA: The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994;169:968-974.
15. Ping LH, Nelson JA, Hoffman IF, et al.: Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: Under representation of X4 variants. J Virol 1999;73:6271-6281.
16. Gupta P, Urbach A, Cosentino L, et al.: HIV- 1 isolates from children with or without AIDS have similar in vitro biologic properties. AIDS 1993;7:1561-1564.
17. Hutto C, Zhou Y, He J, et al.: Longitudinal studies of viral sequence, viral phenotype, and immunologic parameters of human immunodeficiency virus type 1 infection in perinatally infected twins with discordant disease course. J Virol 1996;70:3589-3598.
18. Fitzggibon JE, Gaur S, Gavai M, et al.: Effect of the HIV-1 syncytium-inducing phenotype on disease stage in vertically-infected children. J Med Virol 1998;55:56-63.
19. McCarthy M, He J, Auger D, et al.: Cellular tropisms and coreceptor usage of HIV-1 isolates from vertically infected children with neurological abnormalities and rapid disease progression. J Med Virol 2002;5:67:1-8.
20. Tovo PA, de Martino M, Gabiano C, et al.: Prognostic factors and survival in children with perinatal HIV-1 infection. The Italian Register for HIV Infections in Children. Lancet 1992;339:1249-1253.
21. Bobat R, Coovadia H, Moodley D, et al.: Mortality in a cohort of children born to HIV-1 infected women from Durban, South Africa. South African Med J 1999;89:646-648.
22. Brumme Z, Goodrich J, Mayer H, et al.: Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005;192:466-474.
23. Moyle G, Wildfire A, Mandalia S, et al.: Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005;191:866-872.
24. Isaac C, Tonie C, Polly W, et al.: Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. AIDS Res Hum Retroviruses 2006;22:458-465.
25. Poveda E, Briz V, de Mendoza C, et al.: Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. J Med Virol 2007;79:1040-1046.
26. Elizabeth RJ, Lynn SZ, Solomon M, et al.: High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol 2003,77:7682-7688.
27. Peter WH, Richard PH, Wei H, et al.: Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 2006;194:926-930.
28. Tom M, Michael D, Ralph D, et al.: HIV-1 co receptor use in triple-class treatment-experienced patients: Baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis 2006;194:238-246.
29. Timothy JW, Zhaohui S, Daniel RK, et al.: HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007;44:591-595.
30. Pierre D, Karine S, Michelle C, et al.: R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005;38:382-392.
31. Ndembi N, Yumo H, Takehisa J, et al.: HIV type 1 infection in pygmy-hunter gatherers is from contact with Bantu rather than from non human primates. AIDS Res Hum Retroviruses 2003;19:441-445.
32. Xiao L, Owen SM, Goldman I, et al.: CCR5 co-receptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: Delineation of consensus motif in the V3 domain that predicts CCR5 usage. Virology 1998;240:83-92.
33. Hung CS, Vander HN, Ratner L, et al.: Analysis of the critical domain of V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization. J Virol 1999;73:8216-8226.
34. DeJong JJ, De Ronde A, Keulen W, et al.: Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: Analysis by single amino-acid substitution. J Virol 1992;66:6777-6780.
35. Fouchier RA, Groenink M, Kootstra NA, et al.: Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992;66:3183-3187.
36. Briggs DR, Tuttle DL, Sleasman JW, et al.: Envelope V3 amino acid sequence predicts HIV-1 phenotype (coreceptor usage and tropism for macrophage). AIDS 2000;14:2937-2939.
37. Luzuriaga K, Koup RA, Pikora CA, et al.: Deficient human immunodeficiency virus type 1-specific cytotoxic T cell responses in vertically infected children. J Pediatr 1991;119:230-236.
38. Ljunggren K, Moschese V, Broliden PA, et al.: Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J Infect Dis 1990;161:198-202.
39. Ho S, Shek L, Li A, et al.: Co-receptor switch in a macaque infected with CCR5 (R5)-tropic simian-human immunodeficiency virus. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25-28, 2007 [abstract 71LB].
40. Albert J, Stalhandske P, Marquina S, et al.: Biological phenotype of HIV type 2 isolates correlates with V3 genotype. AIDS Res Hum Retroviruses 1996;12:821-828.
41. Michael NL, Chang G, Ehrenberg PK, Vahey MT, et al.: HIV-1 proviral genotypes from the peripheral blood mononuclear cells of an infected patient are differentially represented in expressed sequences. J Acquir Immune Def Syndr 1993;6:1073-1085.